A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
SARS-CoV-2 Infection
Bottom Line
View on ClinicalTrials.gov: NCT04811664 ↗Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Moderna COVID-19 Vaccine (Biological)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Primary completion
- Dec 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection |
12.2; 31.8; 89.6 | — |
| PRIMARY Effect of Moderna COVID-19 Vaccine on Mean Peak Nasal Viral Load |
25.8; 20.2; 22.3; 26.3; 20.7; 22.8 | — |
| PRIMARY Effect of Moderna COVID-19 Vaccine on Median Peak Nasal Viral Load |
23.9; 19.6; 21.0; 24.3; 20.0; 21.3 | — |
| SECONDARY Efficacy of Moderna COVID-19 Vaccine Against COVID-19 Disease Confirmed by PCR Test and Symptoms |
— | — |
| SECONDARY Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection Regardless of Baseline Negativity |
11.7; 28.3; 76.0 | — |
| SECONDARY Impact of Moderna COVID-19 Vaccine on Secondary Transmission of SARS-CoV-2 Infection |
— | — |
| SECONDARY Efficacy of Moderna COVID-19 Vaccine to Prevent Serologically Confirmed SARS-CoV-2 Infection |
— | — |
| SECONDARY Efficacy of Moderna COVID-19 Vaccine Against COVID-19 Disease Confirmed by PCR Test and Symptoms |
— | — |
| SECONDARY Effect of Moderna COVID-19 Vaccine on Magnitude of Viral Load Over Time |
— | — |
| SECONDARY Efficacy of Moderna Vaccine Regardless of Baseline Serostatus (SARS-CoV-2 Infection by PCR) |
— | — |
| SECONDARY Effect of Moderna Vaccine on Viral Load Regardless of Baseline Serostatus (Viral Load) |
— | — |
| SECONDARY Effect of Moderna Vaccine on Secondary Status Regardless of Baseline Serostatus (Secondary Transmission Events) |
— | — |
| SECONDARY Immunogenicity of Moderna COVID-19 Vaccine |
— | — |
| SECONDARY Immune Responses as Correlates of Risk of SARS-CoV-2 Acquisition, Viral Load, Secondary Infection, and COVID-19 Disease |
— | — |
| SECONDARY Efficacy of Moderna COVID-19 Vaccine Against Asymptomatic SARS-CoV-2 Infection |
— | — |
| SECONDARY Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection and COVID-19 Disease |
— | — |
| SECONDARY Effect of Moderna COVID-19 Vaccine on Viral Load |
— | — |
| SECONDARY Effect of Moderna COVID-19 Vaccine on Secondary Transmission |
— | — |
Summary
Eligibility Criteria
Inclusion criteria for Main cohort, Vaccine Declined Group General and Demographic Criteria
- Age of 18 through 29 years.
- Ability and willingness to provide informed consent.
- Prefers not to receive COVID-19 vaccine.
- Willingness to be followed for the planned duration of the study.
- Assessment of understanding: volunteer demonstrates understanding of this study; completes a questionnaire with demonstration of understanding of all questionnaire items answered incorrectly.
- Access to device and internet for completion of study procedures.
Exclusion criteria for Main cohort, Vaccine Declined Group
- Prior administration of a coronavirus (SARS-CoV-2, SARS-CoV, MERS-CoV) vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19 (participation in studies of other investigational research agents allowed).
- Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, or a volunteer's ability to give informed consent.
Inclusion criteria for Prospective Close Contact (PCC) cohort
- Age of 18 years or older, at the time of signing the informed consent.
- Willing and able to provide informed consent.
- Expected to be in frequent close physical proximity with Main Cohort participant during the study.
- Willing to share results of SARS-CoV-2 testing.
- Access to device and internet for completion of study procedures
Inclusion criteria for Case-ascertained Close Contact (CACC) cohort
- Age of 18 years or older, at the time of signing the informed consent.
- Willing and able to provide informed consent.
- Access to device and internet for completion of study procedures.
- Willing to share results of SARS-CoV-2 testing.
- Had close contact with Main Cohort participant with known PCR-confirmed SARS-CoV-2 infection (eg, index case). Close contacts will have had exposure to the index participant, generally within 72 hours of an index diagnosis, and may include individuals that meet any of the following guidelines:
Prolonged close physical proximity with Main Cohort participant within a residence/vehicle/enclosed space without maintaining social distance,
Medical staff, first responders, or other care persons who cared for the index case without appropriate personal protective equipment.
Further information on the definition of close contact can be found in the CoVPN 3006 Study Specific Procedures (SSP).
Data sourced from ClinicalTrials.gov (NCT04811664). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.